HLB Therapeutics Co., Ltd.

As of March 31, 2026, HLB Therapeutics Co., Ltd. carries a market capitalization of 256.97B, placing it among publicly traded companies globally. Its enterprise value stands at 302.73B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, HLB Therapeutics Co., Ltd. has 88.15M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 3.80, and the price-to-book ratio stands at 1.70.

These figures are as of March 31, 2026. The EV/Sales ratio of 4.48 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 302.73B versus a market cap of 256.97B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, HLB Therapeutics Co., Ltd. maintains a current ratio of 1.34, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 22.91, indicating elevated leverage, while an interest coverage ratio of -3.03 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, HLB Therapeutics Co., Ltd. posted a negative return on equity (ROE) of -5.96, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.01, reflecting losses generated across the asset base. The company generates approximately 931.87M in revenue per employee across its workforce of 72.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 9.64 indicates how many times HLB Therapeutics Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, HLB Therapeutics Co., Ltd. recorded an income tax benefit of -1.42B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -10.99B and -9.09B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, HLB Therapeutics Co., Ltd.'s stock has declined approximately 10.54% over the past 52 weeks. The 50-day moving average sits at 2,343.36, while the 200-day moving average is 2,656.01.

Over the twelve months ended March 31, 2026, HLB Therapeutics Co., Ltd. generated 67.56B in revenue and converted that into -9.09B in net income, yielding earnings per share of -108.55. EBITDA reached -1.76B, while operating income came in at -5.19B.

As of March 31, 2026, HLB Therapeutics Co., Ltd. holds 19.33B in cash and equivalents against 40.32B in total debt, resulting in a net debt position of 18.82B. Total book value stands at 151.25B, with working capital of 11.88B providing operational flexibility.

HLB Therapeutics Co., Ltd. produced -6.65B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -8.32B in capital expenditures, free cash flow totaled -14.97B - equivalent to -169.86 per share.

Over the twelve months ended March 31, 2026, HLB Therapeutics Co., Ltd. posted a gross margin of 10.95, reflecting its pricing power and cost economics. The operating margin of -7.68 and net profit margin of -13.45 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -5.83: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.84, meaning HLB Therapeutics Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

HLB Therapeutics Co., Ltd.'s most recent stock split took place on March 12, 2026 with a 20:21 split ratio.

As of March 31, 2026, HLB Therapeutics Co., Ltd. has an Altman Z-Score of 3.47, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.